Finanzas de Boston Scientific Corp (BSX)BSXBoston Scientific Corp

Boston Scientific Corp (BSX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Electrophysiology, accounting for 16.6% of total sales, equivalent to $840.00M. Other significant revenue streams include Endoscopy and Interventional Cardiology Therapies. Understanding this composition is critical for investors evaluating how BSX navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Boston Scientific Corp maintains a gross margin of 64.81%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 21.76%, while the net margin is 16.63%. These profitability ratios, combined with a Return on Equity (ROE) of 15.52%, provide a clear picture of how effectively BSX converts its operational activities into shareholder value.

In the context of the broader market, BSX competes directly with industry leaders such as BDX and EW. With a market capitalization of $63.53B, it holds a leading position in the sector. When comparing efficiency, BSX's gross margin of 64.81% stands against BDX's 46.76% and EW's 77.46%. Such benchmarking helps identify whether Boston Scientific Corp is trading at a premium or discount relative to its financial performance.

Boston Scientific has shown strong revenue growth, with Q2 2026 revenue at $5.44 billion, up from $5.06 billion in Q2 2025. The gross margin remains robust at 64.81% for Q2 2026, indicating solid profitability.